-- 据彭博社周一援引知情人士报道，意大利制药公司Angelini Pharma正在考虑收购Catalyst Pharmaceuticals (CPRX)。 消息人士称，Angelini正在与顾问合作，谈判尚处于初步阶段，交易能否达成尚无定论。 报道称，这家意大利制药商也在评估其他潜在收购目标，而Catalyst也可能吸引其他潜在买家的兴趣。 Catalyst和Angelini均未立即回复的置评请求。 （市场动态新闻来源于与全球市场专业人士的对话。我们认为这些信息来自可靠来源，但可能包含传闻和猜测。我们不保证其准确性。）
Price: $30.29, Change: $+2.92, Percent Change: +10.67%
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.